Celldex Therapeutics buy Guggenheim
Start price
27.02.24
/
50%
€47.20
Target price
27.02.25
€82.92
Performance (%)
-14.83%
Price
06.09.24
€39.00
Summary
This prediction is currently active. The prediction for Celldex Therapeutics disappoints with a performance of -14.83%. This prediction currently runs until 27.02.25. The prediction end date can be changed by Guggenheim at any time. Guggenheim has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Celldex Therapeutics | 8.333% | 8.333% |
iShares Core DAX® | -3.429% | 3.133% |
iShares Nasdaq 100 | -6.121% | -1.433% |
iShares Nikkei 225® | -7.364% | 1.018% |
iShares S&P 500 | -4.366% | 0.247% |
Comments by Guggenheim for this prediction
In the thread Celldex Therapeutics diskutieren
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for CLDX provided by MarketBeat